Clinical Trials

The ITN conducts clinical trials with the goal of achieving immune tolerance for patients. To see a list of ITN's clinical trials that are currently enrolling participants, please select a disease area: 

Allergy & Asthma          Autoimmune Disease          Transplantation         Type 1 Diabetes

To see all of ITN's active and completed studies, please visit For Researchers.

Active

Daratumumab For Antiphospholipid Syndrome (DARE-APS)

Principal Investigator:
Doruk Erkan, MD, MPH, Hospital for Special Surgery
Jason Knight, MD, PhD, University of Michigan
A study about the safety of daratumumab in patients with antiphospholipid syndrome (APS), and its effectiveness at reducing the antiphospholipid antibodies that cause APS.
Learn more: Study Summary Clinicaltrials.gov Study Website

Measuring Allospecific Impact of Belatacept/Carfilzomib Desensitization (ADAPT)

Principal Investigator:
Stuart Knechtle, MD, Duke University Hospital
The goal of the ADAPT study is to study whether using two drugs, carfilzomib and belatacept, together can lower the number of plasma cells in “highly sensitized” people on the kidney transplant waiting list.
Learn more: Study Summary Clinicaltrials.gov Study Website

Daratumumab plus belatacept desensitization trial (ATTAIN)

Principal Investigator:
Flavio G. Vincenti, MD, University of California, San Francisco Medical Center
The goal of ATTAIN is to study whether using two drugs, daratumumab and belatacept, together can lower the number of plasma cells in “highly sensitized” people on the kidney transplant waiting list.
Learn more: Study Summary Clinicaltrials.gov Study Website

Targeting IL-15 For The Treatment Of Vitiligo (REVEAL)

Principal Investigator:
Brett King, MD, PhD, Yale University
The REVEAL study will investigate whether the experimental study medication, AMG714, can bring back normal color to the skin in vitiligo.
Learn more: Study Summary Clinicaltrials.gov Study Website

Belimumab and Rituximab for Primary Membranous Nephropathy (REBOOT)

Principal Investigator:
Patrick Nachman, MD, University of Minnesota
Ignacio Sanz, MD, Emory University
REBOOT will test whether a combination of, belimumab and rituximab, is safe and if this combination is more effective at blocking the immune attack on the kidney of patients with Primary Membranous Neuropathy (MN).
Learn more: Study Summary Clinicaltrials.gov Study Website

Best Available Therapy Vs. Autologous Hematopoietic Stem Cell Transplant For MS (BEAT MS)

Principal Investigator:
Jeffrey Cohen, MD, Cleveland Clinic
George Georges, MD, Fred Hutchinson Cancer Research Center
Paolo Muraro, MD, PhD, Imperial College London
BEAT-MS is a clinical trial comparing chemotherapy followed by autologous hematopoietic stem cell transplant (AHSCT) – a type of bone marrow transplantation – to the most effective medicines regularly used to treat relapsing MS.
Learn more: Study Summary Clinicaltrials.gov Study Website

Vaginal Microbiome Exposure and Immune Responses in C-section Infants (ACTIVATE)

Principal Investigator:
Hugh Sampson, MD , Icahn School of Medicine at Mount Sinai , New York
Jose Clemente, PhD , Icahn Institute for Genomics and Multiscale Biology , New York
ACTIVATE is a clinical trial investigating the impact of the infant microbiome on allergy development.
Learn more: Study Summary Clinicaltrials.gov Study Website

T1D Extended Study (T1DES)

Principal Investigator:
Linda DiMeglio, MD, MPH, Indiana University and Riley Hospital for Children, Indianapolis, IN
T1DES is a clinical study for people with type 1 diabetes who were previously enrolled in an ITN clinical study.
Learn more: Study Summary Clinicaltrials.gov Study Website
View All Clinical Trials